APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Study Intervention Participants Outcomes<br />
Core symptoms<br />
Abbreviated Conners’ Questionnaire (parents,<br />
teachers)<br />
Loney <strong>and</strong> Milich’s Inattention/Overactivity<br />
<strong>and</strong> Aggression (non-compliance) scales<br />
(parents, teachers)<br />
Reference<br />
Klorman et al.,<br />
1987 66,304<br />
Source<br />
AHRQ Report<br />
Co-existent problems<br />
Not reported<br />
Inclusion criteria<br />
1. 2 SDs above mean on Abbreviated Conners’ Hyperactivity<br />
Questionnaire<br />
2. 2 SDs above mean on Home Activity Scale<br />
3. No evidence <strong>of</strong> organic brain disorder, psychosis or<br />
uncorrected sensory impairment<br />
4. IQ score =74 on WAIS-R or WISC-R<br />
5. No MPH treatment for 2 weeks or MPH/thioridazine<br />
treatment for 4 weeks preceding trial<br />
Arm 1<br />
MPH<br />
Week 1: 10 mg at breakfast <strong>and</strong><br />
lunch; 5 mg at 4 p.m.<br />
Weeks 2 <strong>and</strong> 3: 15 mg at breakfast<br />
<strong>and</strong> lunch; 10 mg at 4 p.m.<br />
(Individual administering medication<br />
not reported)<br />
Setting<br />
USA<br />
Educational performance<br />
Not reported<br />
Arm 2<br />
Placebo (PLA)<br />
Lactose capsules administered 3 times<br />
daily (breakfast, lunch, 4 p.m.)<br />
(Individual administering medication<br />
not reported)<br />
Design<br />
Crossover trial<br />
Psychological function<br />
Not reported<br />
Diagnostic criteria<br />
See inclusion criteria<br />
Number<br />
Total r<strong>and</strong>omised = 19 (male = 16)<br />
Arm 1 = 19<br />
Arm 2 = 19<br />
Duration<br />
Total treatment period:<br />
6 weeks (3 weeks per<br />
treatment arm)<br />
Depression or anxiety<br />
Mood ratings: dysphoria, euphoria, anxiety,<br />
differentness<br />
No withdrawals reported<br />
Quality <strong>of</strong> life<br />
Loney <strong>and</strong> Ordona Scale: response (patients,<br />
parents)<br />
Age<br />
14.80 years (mean); 1.91 years (SD); 12–19 years (range)<br />
Purpose<br />
To determine whe<strong>the</strong>r<br />
MPH has a similar<br />
beneficial impact on<br />
ADD adolescents as<br />
previously found for<br />
prepubertal ADD<br />
patients<br />
© Queen’s Printer <strong>and</strong> Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
Adverse events<br />
STESS (based on interviews with parent <strong>and</strong><br />
patient)<br />
IQ<br />
100.58 (mean)<br />
Health Technology Assessment 2006; Vol. 10: No. 23<br />
Co-morbid disorders<br />
Not reported<br />
Additional outcomes<br />
EKG recordings<br />
Diagnostic subtypes<br />
Not reported<br />
Additional information<br />
Previous medication:<br />
13/19 had been treated with MPH, sometimes supplemented<br />
with thioridazine. 5/19 had never received medication. 1/19 had<br />
previously received PEM<br />
Participants were required not to receive MPH for 2 weeks or<br />
combined MPH/thiroridazine treatment for 4 weeks preceding<br />
<strong>the</strong> trial<br />
283
Change language